GlassScriptPhysician profile
Thomas J Oneill
NPI 1467452706
$6,429.22
in general payments reported to CMS, 2019-2025
29 companies · $34.60 in 2025
The $34.60 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,711 · 2020: $1,533 · 2021: $2,138 · 2022: $12.63 · 2025: $34.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $34.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $34.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,741.70 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $1,294.68 | 2019-2021 | |
| Genzyme Corporation | $406.67 | 2019-2021 | |
| Philips North America LLC | $387.42 | 2019-2021 | |
| Genentech USA, INC. | $278.89 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $267.53 | 2019-2020 | |
| Mylan Specialty L.P. | $254.32 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $206.99 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $188.05 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.70 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $152.80 | 2019 | |
| Pfizer INC. | $136.01 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $125.10 | 2019 | |
| Electromed, INC. | $112.40 | 2021 | |
| Mallinckrodt Hospital Products INC. | $106.60 | 2020-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $98.61 | 2020-2022 | |
| Advanced Respiratory, INC | $97.46 | 2019-2021 | |
| Circassia INC. | $67.80 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $59.49 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $55.61 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $35.41 | 2020-2021 | |
| Cvrx, INC. | $34.60 | 2025 | Barostim Neo System |
| Horizon Therapeutics Plc | $34.17 | 2019 | |
| Jazz Pharmaceuticals INC. | $29.89 | 2020 | |
| Sanofi-Aventis U.S. LLC | $25.28 | 2021 | |
| Arbor Pharmaceuticals, INC. | $25.20 | 2021 | |
| Tactile Systems Technology INC | $20.48 | 2021 | |
| Uswm, LLC | $16.15 | 2021 | |
| Amgen INC. | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Oneill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.